- Home
- MDIA vs CUE Comparison
MDIA vs CUE Comparison
Compare MDIA & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDIA
- CUE
- Stock Information
- Founded
- MDIA 2019
- CUE 2014
- Country
- MDIA United States
- CUE United States
- Employees
- MDIA N/A
- CUE N/A
- Industry
- MDIA Broadcasting
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- MDIA Consumer Discretionary
- CUE Health Care
- Exchange
- MDIA Nasdaq
- CUE Nasdaq
- Market Cap
- MDIA 51.8M
- CUE 48.0M
- IPO Year
- MDIA N/A
- CUE 2018
- Fundamental
- Price
- MDIA $1.24
- CUE $0.74
- Analyst Decision
- MDIA
- CUE Strong Buy
- Analyst Count
- MDIA 0
- CUE 3
- Target Price
- MDIA N/A
- CUE $3.00
- AVG Volume (30 Days)
- MDIA 704.2K
- CUE 323.3K
- Earning Date
- MDIA 05-20-2025
- CUE 08-13-2025
- Dividend Yield
- MDIA N/A
- CUE N/A
- EPS Growth
- MDIA N/A
- CUE N/A
- EPS
- MDIA N/A
- CUE N/A
- Revenue
- MDIA $116,895,000.00
- CUE $7,991,000.00
- Revenue This Year
- MDIA N/A
- CUE N/A
- Revenue Next Year
- MDIA N/A
- CUE $23.84
- P/E Ratio
- MDIA N/A
- CUE N/A
- Revenue Growth
- MDIA 268.03
- CUE 13.83
- 52 Week Low
- MDIA $0.79
- CUE $0.45
- 52 Week High
- MDIA $5.73
- CUE $1.99
- Technical
- Relative Strength Index (RSI)
- MDIA 53.84
- CUE 51.10
- Support Level
- MDIA $1.11
- CUE $0.65
- Resistance Level
- MDIA $1.38
- CUE $0.83
- Average True Range (ATR)
- MDIA 0.12
- CUE 0.07
- MACD
- MDIA 0.01
- CUE 0.01
- Stochastic Oscillator
- MDIA 51.11
- CUE 30.43
About MDIA Mediaco Holding Inc.
MediaCo Holding Inc is a radio broadcasting media company operating in radio and digital advertising, premium programming, and events. It has two radio stations, WQHT-FM and WBLS-FM, which serve the New York City metropolitan area. The company generates revenue from radio and outdoor advertising sales, events including sponsorships and ticket sales, licensing, and syndication. The company has two business segments: the Audio segment and the Video segment. The company generates the majority of its revenue from the Audio segment.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.